Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
Abstract
Brentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies.
Downloads
References
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703-14. doi:10.1182/blood.2019002852.
Di Raimondo C, Parekh V, Song JY, Rosen ST, Querfeld C, Zain J, et al. Primary cutaneous CD30+ lymphoproliferative disorders: a comprehensive review. Curr Hematol Malig Rep. 2020;15:333-42. doi: 10.1007/s11899-020-00583-4.
Khan S, Sawas A. Antibody-directed therapies: toward a durable and tolerable treatment platform for CTCL. Front Oncol. 2019;9:645. doi:10.3389/fonc.2019.00645
Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024-35. doi: 10.1182/blood-2011-05-351346.
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lym- phomas: ESMO Clinical Practice Guidelines for diagno- sis, treatment and follow-up. Ann Oncol. 2018;29:iv30-iv40. doi: 10.1093/annonc/mdy133.
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33:3750-8. doi:10.1200/JCO.2014.60.3969
Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759-65. doi: 10.1200/JCO.2014.60.3787.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30- positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555-66. doi: 10.1016/S0140-6736(17)31266-7.
Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom HS, et al. Efficacy of Brentuximab Vedotin in Relapsed or RefractoryHigh-CD30-ExpressingNon-HodgkinLymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Res Treat. 2020;52:374-87. doi: 10.4143/crt.2019.198.
Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759-65. doi: 10.1200/JCO.2014.60.3787.
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33:3750-8. doi: 10.1200/JCO.2014.60.3969.
Stranzenbach R, Dippel E, Schlaak M, Stadler R. Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br J Dermatol. 2017;177:1503-09. doi: 10.1111/bjd.15801.
Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
